Denied Claims and Appeals

Payers may reject a prior authorization request or procedure claims for a variety of reasons. Reasons for denial may include:

  • Clerical errors such as misspellings and transposed numbers
  • Questions about medical necessity
  • Unfamiliarity with the class of drug
  • Improper use of codes
  • Insufficient documentation/missing information

Denied coverage or claims may be appealed and potentially reversed. Submitting supporting documentation is a strong factor in the review process. Claims submitted with proper coding and documentation will reduce the likelihood of denials because of technical errors or product unfamiliarity. The following may serve as a guide to the appeals process.

Step One

Review the reasons for the denied claims. Typically, denial codes or written details will accompany the decision. Identify any previously approved SUPPRELIN® LA implants from the same payer.

Step Two

Determine the payer's algorithm for appealing denied claims, including contact information and appeals locations. Typically this information is listed in your provider plan. Medicare contractors provide appeals information on their websites. Submitting documentation to justify the medical necessity of SUPPRELIN LA for the patient may be required. Items to include in the submission to the insurer should include:

  • Letter of Medical Necessity, highlighting:
    • The patient's medical condition
    • Severity of the disease and medical history
    • Rationale for SUPPRELIN LA (how it may improve the patient's condition)
    • Risks of foregoing SUPPRELIN LA
  • Reprints (not photocopies) of peer-reviewed clinical articles and abstracts
  • Referring physician letter and/or medical history

Step Three

If denied after the first appeal, active physician involvement may be required to engage the payer and establish medical necessity for the patient. The physician should consider the following options in the appeals process:

  • Write a letter of appeal
  • Contact the medical director of the payer to present this patient's case
  • Discuss alternative payment options with the patient's caregivers
  • Consider potential patient advocacy campaign

Step Four

Patients may play an important role in the appeals process. The patient’s plan brochure provides information on claim appeals. Please instruct the family to refer to this document or access the plan’s website for appeals information. Several patient advocacy options may be considered for overturning coverage or claim denials:

  • Encourage patient to contact his/her employer’s benefits manager to discuss the situation
  • Suggest the family write an appeal letter
  • Ask the family to contact the medical director or head of customer or patient relations
  • Request that the plan reconsider the original denial

The SUPPRELIN® LA Support Center is available Monday-Friday from 8AM - 6PM EST. toll-free at 1-855-270-0123.


Indication

SUPPRELIN® LA (histrelin acetate) subcutaneous implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

  • SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

  • SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

  • Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

  • During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.